Codexis, Inc. (CDXS): Price and Financial Metrics

Codexis, Inc. (CDXS): $25.57

-0.21 (-0.81%)

POWR Rating

Component Grades













Add CDXS to Watchlist
Sign Up

Industry: Biotech


of 504

in industry


  • Quality is the dimension where CDXS ranks best; there it ranks ahead of 53.62% of US stocks.
  • The strongest trend for CDXS is in Quality, which has been heading down over the past 48 weeks.
  • CDXS's current lowest rank is in the Value metric (where it is better than 6.35% of US stocks).

CDXS Stock Summary

  • The ratio of debt to operating expenses for Codexis Inc is higher than it is for about just 21.92% of US stocks.
  • With a price/sales ratio of 20.1, Codexis Inc has a higher such ratio than 90.34% of stocks in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.33 for Codexis Inc; that's greater than it is for just 17.79% of US stocks.
  • Stocks that are quantitatively similar to CDXS, based on their financial statements, market capitalization, and price volatility, are ENTX, SDGR, INSM, FBIO, and INFN.
  • Visit CDXS's SEC page to see the company's official filings. To visit the company's web site, go to

CDXS Valuation Summary

  • In comparison to the median Healthcare stock, CDXS's price/earnings ratio is 304.93% lower, now standing at -74.8.
  • Over the past 138 months, CDXS's price/sales ratio has gone up 15.7.
  • CDXS's price/sales ratio has moved up 15.7 over the prior 138 months.

Below are key valuation metrics over time for CDXS.

Stock Date P/S P/B P/E EV/EBIT
CDXS 2021-08-31 21.1 10.7 -74.8 -70.3
CDXS 2021-08-30 20.6 10.5 -73.1 -68.6
CDXS 2021-08-27 20.8 10.6 -73.8 -69.3
CDXS 2021-08-26 19.8 10.1 -70.2 -65.6
CDXS 2021-08-25 20.2 10.3 -71.8 -67.3
CDXS 2021-08-24 19.2 9.8 -68.2 -63.7

CDXS Growth Metrics

  • The 3 year net cashflow from operations growth rate now stands at -452.1%.
  • Its 4 year price growth rate is now at 281%.
  • The 5 year net cashflow from operations growth rate now stands at -343.94%.
Over the past 33 months, CDXS's revenue has gone up $16,654,000.

The table below shows CDXS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 82.903 -19.701 -23.347
2021-03-31 72.417 -21.479 -25.426
2020-12-31 69.056 -16.464 -24.01
2020-09-30 66.672 -18.633 -20.725
2020-06-30 70.193 -16.149 -14.288
2020-03-31 67.545 -11.134 -14.451

CDXS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CDXS has a Quality Grade of C, ranking ahead of 53.62% of graded US stocks.
  • CDXS's asset turnover comes in at 0.423 -- ranking 64th of 90 Chemicals stocks.
  • NGVT, IFF, and GPP are the stocks whose asset turnover ratios are most correlated with CDXS.

The table below shows CDXS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.423 0.782 -0.333
2021-03-31 0.406 0.787 -0.370
2020-12-31 0.424 0.801 -0.359
2020-09-30 0.461 0.831 -0.313
2020-06-30 0.479 0.819 -0.220
2020-03-31 0.457 0.796 -0.237

CDXS Price Target

For more insight on analysts targets of CDXS, see our CDXS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $29.50 Average Broker Recommendation 1.31 (Strong Buy)

CDXS Stock Price Chart Interactive Chart >

Price chart for CDXS

CDXS Price/Volume Stats

Current price $25.57 52-week high $29.56
Prev. close $25.78 52-week low $11.56
Day low $25.34 Volume 149,100
Day high $25.79 Avg. volume 508,005
50-day MA $24.09 Dividend yield N/A
200-day MA $22.70 Market Cap 1.65B

Codexis, Inc. (CDXS) Company Bio

Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States and internationally. The company offers Codex biocatalyst panels and kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. The company was founded in 2002 and is based in Redwood City, California.

CDXS Latest News Stream

Event/Time News Detail
Loading, please wait...

CDXS Latest Social Stream

Loading social stream, please wait...

View Full CDXS Social Stream

Latest CDXS News From Around the Web

Below are the latest news stories about Codexis Inc that investors may wish to consider to help them evaluate CDXS as an investment opportunity.

Codexis, Merck Extend Supply Pact For Enzyme Used To Manufacture Sitagliptin

Codexis Inc (NASDAQ: CDXS) has amended and extended its agreement with Merck & Co Inc (NYSE: MRK) to license and supply a proprietary enzyme used to manufacture sitagliptin. Sitagliptin is an active pharmaceutical ingredient (API) in Merck's two anti-diabetic medications, Januvia and Janumet. Codexis and Merck leveraged Codexis' CodeEvolver enzyme engineering platform technology to design an enzyme to serve as a biocatalyst in the sitagliptin manufacturing process. In 2012 Codexis and Merck ente

Yahoo | September 10, 2021

Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin

REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the amendment and extension of its agreement with Merck, known as MSD outside the United States and Canada, to license and supply a proprietary enzyme used in the manufacturing process for sitagliptin, the active pharmaceutical ingredient (API) in Merck’s JANUVIA® and one of the active ingredients in Merck’s JANUMET®. “Co

Yahoo | September 9, 2021

Codexis to Participate in Upcoming Virtual Healthcare Conferences

REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in two upcoming virtual investment conferences. The H.C. Wainwright 23rd Annual Global Investment Conference — September 13, 2021 at 7:00 a.m. ET, on-demand corporate presentation The Cantor Virtual Global Healthcare Conference — September 28, 2021 at 10:40 a.m. ET, fireside chat Webc

Yahoo | September 7, 2021

Codexis Confirms Receipt of Follow-on Orders for Proprietary Enzyme Product from Undisclosed Global Pharmaceutical Company

Orders Support Company’s Recently Increased 2021 Guidance REDWOOD CITY, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the Company received new purchase orders with an aggregate total value of approximately $15 million for the 2021 supply of a proprietary high performance enzyme used to manufacture a critical intermediate for an Active Pharmaceutical Ingredient (API) in a therapeuti

Yahoo | August 25, 2021

After Golden Cross, Codexis (CDXS)'s Technical Outlook is Bright

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Yahoo | August 10, 2021

Read More 'CDXS' Stories Here

CDXS Price Returns

1-mo -1.35%
3-mo 13.44%
6-mo 23.53%
1-year 118.92%
3-year 33.87%
5-year 497.43%
YTD 17.13%
2020 36.52%
2019 -4.25%
2018 100.00%
2017 81.52%
2016 8.75%

Continue Researching CDXS

Here are a few links from around the web to help you further your research on Codexis Inc's stock as an investment opportunity:

Codexis Inc (CDXS) Stock Price | Nasdaq
Codexis Inc (CDXS) Stock Quote, History and News - Yahoo Finance
Codexis Inc (CDXS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9024 seconds.